Armata Pharmaceuticals (ARMP) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($136.5 million vs $133.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | RNA |
|---|---|---|
| Share price | $3.60 | $7.98 |
| Market cap | $133.86M | $136.50M |
| 1-day change | -5.51% | +0.63% |
| YTD return | -39.33% | — |
| 1-year return | +21.34% | — |
| 5-year return | +10.43% | — |
| EPS (TTM) | $-5.29 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $16.77 |
| 52-week low | $3.09 | $7.63 |
| Distance from 52-week high | -77.97% | -52.42% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +386.11% | +213.28% |
| Average volume | 210.93K | 253.00K |
| Shares outstanding | 37.18M | 17.11M |
| Employees | 61 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
ARMP vs RNA FAQ
Which is bigger, Armata Pharmaceuticals or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $136.50M compared with $133.86M for Armata Pharmaceuticals (ARMP).
Are Armata Pharmaceuticals and Atrium Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Armata Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Atrium Therapeutics.